Published articleClinicalMolecular biologyScore8.5
KRAS G12C resistance via Y96D in non-small cell lung cancer
Summary
A multicenter cohort describes Y96D as a KRAS G12C inhibitor resistance mechanism with direct therapeutic implications.
Analysis
The main value is clinical and pharmacogenomic: the alteration changes inhibitor sensitivity and supports longitudinal molecular monitoring.